Logo image
Inefficacy of selegiline in treatment of canine pituitary-dependent hyper-adrenocorticism
Journal article   Peer reviewed

Inefficacy of selegiline in treatment of canine pituitary-dependent hyper-adrenocorticism

J.A. Braddock, D.B. Church, I.D. Robertson and A.D.J. Watson
Australian Veterinary Journal, Vol.82(5), pp.272-277
2004
url
Link to Published Version *Subscription may be requiredView

Abstract

Objective: To evaluate selegiline, a monoamine oxidase-B inhibitor, for treating dogs with pituitary-dependent hyperadrenocorticism. Design: Prospective clinical trial using client-owned dogs with pituitary-dependent hyperadrenocorticism treated at The University Veterinary Centre, Sydney, from September 1999 to July 2001. Procedure: Eleven dogs with pituitary-dependent hyperadrenocorticism treated with selegiline were monitored at days 10, 30 and 90 by clinical examination, tetracosactrin stimulation testing, urinary corticoid:creatinine ratio measurement and client questionnaire. Endogenous adrenocorticotropic hormone measurements were also performed on most dogs on days 0 and 90. Results: No dog treated with selegiline had satisfactory control of disease. Conclusion: Selegiline administration was safe and free of side-effects at the doses used, but did not satisfactorily control disease in pituitary-dependent hyperadrenocorticism affected dogs.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
3 Agriculture, Environment & Ecology
3.232 Veterinary Sciences
3.232.1281 Veterinary Reproductive Health
Web Of Science research areas
Veterinary Sciences
ESI research areas
Plant & Animal Science
Logo image